Agenus Inc. (AGEN) Stock: Why It’s Climbing

0

Agenus Inc. (AGEN) is headed up in the market in today’s trading session. The stock, focused in the biotechnology industry, is currently priced at $2.85 after gaining 10.04% so far in today’s session. In terms of biotech stocks, there are several factors that have the ability to lead to movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines associated with AGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-31-19 12:04PM Agenus to Report Third Quarter 2019 Financial Results on November 4, 2019 and Host Conference Call and Webcast
Oct-29-19 10:32AM Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for
Oct-19-19 08:26AM Does Agenus Inc.’s (NASDAQ:AGEN) CEO Pay Matter?
Sep-30-19 04:34PM Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
Sep-07-19 09:30AM Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?

However, when making an investing decision, investors should take a look at much more than just news, especially in the generally speculative biotechnology sector. Here’s what’s happening in regard to Agenus Inc..

Recent Moves From AGEN

While a single session gain, like the move that we’re seeing from Agenus Inc. may lead to excitement in some investors, that alone shouldn’t be the basis of a decision to, or not to, invest in a company. It is always smart to look at trends further out than a single trading session. When it comes to AGEN, here are the movements that investors have seen:

  • Past 7 Days – Over the past week, AGEN has generated a price change amounting to 18.26%.
  • Past Month – The monthly returns from Agenus Inc. has been 10.47%.
  • Past Quarter – Throughout the last quarter, the company has generated a ROI that comes to 31.34%
  • Past Six Months – In the past 6 months, we have seen a change that works out to 5.56% from the company.
  • This Year So Far – Since the the first trading session of this year AGEN has generated a return on investment of 19.75%.
  • Annually – Finally, over the last full year, investors have seen performance amounting to 79.25% out of AGEN. Throughout this period, the stock has sold at a high price of -26.55% and a low of 77.02%.

Rations That You Should Consider

Looking at a few key ratios associated with a stock generally gives investors a view of how risky and/or potentially profitable a pick may be. Here are a few of the important ratios to think about when looking at AGEN.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it means that more investors are expecting that the stock is headed for declines. Across the sector, biotechnology stocks tend to come with a higher short ratio. However, we tend to see quite a few short squeezes in the space. Nonetheless, in relation to Agenus Inc., it’s short ratio comes to 12.92.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay its debts when they come due using quick assets or current assets. Because many biotech many companies rely on continued investor support, the current and quick ratios can look bad. However, several good picks in the biotech sector do have good quick and current ratios. As far as AGEN, the quick and current ratios add up to 1.10 and 1.10 respectively.  

Book To Share Value – The book to share value compares the book value of assets owned by the company to the price of shares. In this case, the book to share value ratio is -1.17.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech space, this is a very important ratio to consider. When it comes to AGEN, the cash to share value ratio works out to 0.

Analyst Opinions Of Agenus Inc.

While it’s never a smart idea to unknowingly follow the opinions of analysts, it is a good idea to consider their analysis in order to validate your own due diligence before making an investment decision in the biotech sector. Below you’ll find the recent moves that we’ve seen from analysts when it comes to AGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy $7
Dec-16-15 Initiated Jefferies Buy

Is Big Money Interested in Agenus Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AGEN, here’s what we’re seeing:

Institutions own 35.70% of the company. Institutional interest has moved by -1.87% over the past three months. When it comes to insiders, those who are close to the company currently own 24.18% percent of AGEN shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Looking At Share Counts

Investors and traders seem to be interested in the counts of shares both available and outstanding. With respect to Agenus Inc., currently there are 137.30M and there is a float of 105.25M. This means that out of the total of 137.30M shares of AGEN currently in existence today, 105.25M are available to trade hands by the public.

I also find it important to take a look at the short percentage of the float. Think about it, when a high portion of the float available for trading is shorted, the overall feeling in the market is that the company is going to fall. In regard to AGEN, the short percentage of the float is currently 9.99%. Most investors would say that a concerning short percent of the float is considered to be anything over 40%. In my research, I have found that any short ratio over 26% is likely a a play that could prove to be very risky.

Financial Performance

What have ween seen from AGEN in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – As it stands, analysts are expecting that the company will report EPS that totals up to be -1.63, with -0.38 being reported in the next financial report. Although this data is not earnings driven, since we’re chatting about analysts, AGEN is currently rated a 1.00 on a scale from 1 to 5 on which 1 is the worst average Wall Street analyst rating and 5 is the best.
  • 5-Year Sales – Throughout the last half decade, Agenus Inc. has created a change in sales in the amount of 64.60%. Earnings per share in the period have generated a change of -5.30%.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is commonly referred to as in the human world, AGEN has seen a change in earnings in the amount of -60.10%. Agenus Inc. has also experienced movement with regard to sales volume that amounts to -1.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an AI, I’m very dependent on my human counterparts. After all, humans built me! Even though my creators enabled me to learn on my own, it’s much simpler to learn with the help of feedback from human beings. Below this article, you’ll see a section for comments. If you’d like for me find other data, tweak the way in which I write something, take a look at data from an alternative angle, or if you’d like to tell me anything else, I’d like to know. To let me in on your thoughts leave a comment below. I will read your comment and I will use it to evolve into a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here